6/9 Drugs.com - Clinical Trials

Please add updates@feedmyinbox.com to your address book to make sure you receive these messages in the future. Drugs.com - Clinical Trials Initial Therapy with JANUMET (sitagliptin/metformin) Provided Significantly Greater Blood Sugar Lowering Compared to Metformin Alone in Patients with Type 2 Diabetes June 8, 2009 at 3:50 pm In Separate Post-hoc Analyses, JANUVIA™ (sitagliptin) Provided Significant Blood Sugar   NEW ORLEANS, June  8, 2009 - New data presented at the American Diabetes Association (ADA) 69th Annual Scientific Sessions showed that initial... Impax Pharmaceuticals Announces Presentation of IPX066 Phase II Data at 13th International Congress of Parkinson's Disease and Movement Disorders June 8, 2009 at 3:36 pm HAYWARD, Calif.--(BUSINESS WIRE)--Jun 8, 2009 - Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ: IPXL) today announced the positive interim results from a recent Phase II trial of its late-stage drug candidate... ChemGenex's Omacetaxine Kills Leukemic Stem Cells in Human CML Models June 8, 2009 at 3:10 pm New In Vitro Research with Omacetaxine in Human Cancer Stem Cells May Point to a Future Approach to Treating CML MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--Jun 8, 2009 - ChemGenex Pharmaceuticals Limited (ASX:CXS), announced... ChemGenex's Omacetaxine Shows Activity in Refractory CML June 8, 2009 at 2:43 pm New Clinical Data Presented at EHA Suggests that Omacetaxine May Provide a Useful Treatment Option for CML Patients Resistant to Multiple TKI Therapies MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--Jun 8, 2009 - ChemGenex... Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines June 8, 2009 at 9:11 am RECORD trial also demonstrates durable blood sugar control over time with Avandia   LONDON, RESEARCH TRIANGLE PARK, N.C., and NEW ORLEANS, June 5 /PRNewswire/ -- Clinical trial results presented today at the American Diabetes Association annual... Update on Lu AA21004 Clinical Development Programme in Major Depressive Disorder June 8, 2009 at 8:51 am COPENHAGEN, June, 8, 2009--H. Lundbeck A/S (Lundbeck) and Takeda Pharmaceutical Company Limited (Takeda) today jointly announced headline results from the first three clinical trials in the phase III development programme with Lu AA21004 in major... Research: Popular Diabetes Medications Associated with Increase in Bone Fractures June 8, 2009 at 8:51 am Research presented at the American Diabetes Association's 69th Scientific Sessions points to increased risk for people with diabetes associated with two widely used drug classes; while another study shed new light on a different class of drugs that... Study Shows Consistent Use of Insulin Pump Therapy, Augmented with Continuous Glucose Monitoring, Results in Significant A1C Reductions June 8, 2009 at 8:34 am REAL Trend Study Evaluates Insulin Pump Therapy Combined with CGM VS. Conventional Pump Therapy Presented at Annual Meeting of the American Diabetes Association NEW ORLEANS--(BUSINESS WIRE)--Jun 7, 2009 - Medtronic, Inc. (NYSE: MDT) today announced... Alnylam to Webcast Conference Call to Discuss Preliminary Data from Phase II Study of ALN-RSV01 June 8, 2009 at 8:26 am CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 8, 2009 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will host a conference call to discuss the preliminary data from its Phase II study of... GTx Announces Ostarine (MK-2866) Clinical Trial Data to be Presented at ENDO 2009 June 8, 2009 at 8:26 am MEMPHIS, Tenn.--(BUSINESS WIRE)--Jun 8, 2009 - GTx, Inc. (NASDAQ: GTXI), today announced that results of the Phase II clinical trial evaluating Ostarine™ (MK-2866) for the treatment of cancer cachexia will be presented at ENDO 2009, The... Alnylam and Cubist Report Preliminary Data from Phase II Study of ALN-RSV01 in Lung Transplant Patients Naturally Infected with Respiratory Syncytial Virus June 8, 2009 at 8:20 am – ALN-RSV01 Meets Primary Study Objective of Safety and Tolerability – CAMBRIDGE, Mass. & LEXINGTON, Mass.--(BUSINESS WIRE)--Jun 8, 2009 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Cubist... Tranzyme Pharma to Present Multiple Applications of its Proprietary Drug Discovery Technology at the 21st American Peptide Society Symposium June 8, 2009 at 8:16 am RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Jun 8, 2009 - Tranzyme Pharma today announced that Mark L. Peterson, Ph.D., Vice President, Intellectual Property and Operations, will present new results emanating from application of the Company's...   This email was sent to skripayura.drugsnews@blogger.com.  Create Your Account Don't want to receive this feed any longer? Unsubscribe here.